Cantor Fitzgerald reiterates Evommune stock rating at Overweight

Cantor Fitzgerald reaffirmed its Overweight rating on Evommune Inc (NYSE:EVMN) following a reassessment of the company's operating expenses. The rating adjustment was prompted by recent updates from the company itself. However, the research firm noted that five analysts had recently reduced their earnings estimates for Evommune Inc, and the company was noted for its rapid cash burn.

Cantor Fitzgerald's updated projections indicated a larger earnings per share loss for 2026 and 2027, yet the firm's rating remained unchanged. Currently trading at $9.37, the stock is close to its 52-week low of $9.30 and has slipped 11% in the past week. Despite these challenges, InvestingPro analysts consider the stock potentially undervalued, a viewpoint that can be further explored on their undervalued stocks list.

Evommune Inc also faced setbacks with its EVO756 drug candidate failing to meet primary and secondary endpoints in a recent Phase 2b trial for atopic dermatitis, leading the company to discontinue development of this particular drug. Analyst reactions to these developments have been diverse, with some maintaining positive ratings while others expressed more cautious outlooks.